MedTrace Logo

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

NCT03181113 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 473

Last updated 2021-04-13

No results posted yet for this study

Summary

In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.

Conditions

Interventions

DRUG

Peginterferon Alfa-2B

pre-received standard peginterferon alfa-2b therapy

DRUG

Peginterferon Alfa-2A

pre-received standard peginterferon alfa-2a therapy

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Xiamen Amoytop Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Guiqiang Wang, MD · Peking University First Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-18
Primary Completion
2020-09-21
Completion
2020-09-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03181113 on ClinicalTrials.gov